Zaans Medisch Centrum Stichting

Zaandam 24 trials 10 recruiting

24 Registered trials

10 Currently recruiting

Organisation

Zaans Medisch Centrum Stichting

Location

Zaandam, Netherlands

Identifier

ORG-100043926

Address

Koningin Julianaplein 58, 1502 DV, Netherlands

Departments

-
Cardiologie
Cardiology
Gynaecologie
Gynaecology
Hartvaatcentrum
Hematology
Internal medicine/Oncology
interne geneeskunde
Interne Oncologie
N/A
Neurology
Oncologie
Oncology
Pulmonary Medicine
Pulmonology
Research Cardiology
Surgery

Clinical trials at this site (24)

Search interface

Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
Laparoscopic Antibiotic Lavage to Prevent intra-abdominal Abscess formation in Complicated Appendicitis (ALPACA) Recruiting

2024-514850-59-00 Appendicitis 5 2025-02-24
Oil- based versus water-based contrast media for hysterosalpingography (HSG) in infertile women with unevaluated indications: a randomized c… Recruiting

2024-512571-12-00 Infertility 6 2024-11-29
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting

2023-509706-30-00 Heart failure (HF) 5 2024-10-18
DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting

2023-506115-17-00 Metastatic Colorectal Cancer 5 2024-10-14
Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NV… Recruiting

2024-516195-15-00 Advanced NSCLC 5 2024-09-10
PEPPER-trial Recruiting

2023-507763-18-01 Placenta previa, preterm birth 6 2024-05-21
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
VulVaccin study Recruiting

2023-506792-94-00 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSI 11 2024-03-04
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended

2022-502664-21-00 multiple sclerosis 6 2023-05-01
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended

2024-516205-23-00 Breast cancer 4 2019-04-09
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who… Ended

2023-510557-42-00 chronic lymphocytic leukemia 4 2017-07-10
Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN) Ended

2024-516581-11-00 Advanced stage NSCLC 5